The Public Prosecutor filed the documents of the maxi investigation which led to the arrest, in May 2017, of 19 people and which shocked the Parma health system
The Public Prosecutor of Parma filed the documents of the maxi Pasimafi investigation, a real earthquake for the Parma health system which had led to the arrest, at dawn on 8 May, of 19 people including doctors, pharmaceutical entrepreneurs and owners of pharmaceutical companies, including Guido Fanelli, the then head of the Second Anesthesia and Intensive Care Unit of the Ospedale Maggiore of Parma. Criminal association aimed at corruption and money laundering, implemented in the field of health experimentation and scientific dissemination to promote the commercial activities of national and foreign pharmaceutical companies: these were the charges for the people involved. With the closure of the investigations and the filing of the documents, the Public Prosecutor's Office entered 8 other doctors in the register of suspects: Antonio Mutti, head of Occupational Medicine and director of the Department of Medicine and Surgery, Maria Luisa Rita Caspani, former number one of the First Anesthesia, Susanna Biondini, Fabiana Salici, Raffaella di Pasquale, Adriana Valente, Michelina Ferro and Dario Bugada, doctors of the Second Anesthesia and Intensive Care. In total, the number of suspects thus rises to 87: for eleven people and two companies, the Prosecutor of the Republic of Parma has asked for the filing.
Pasimafi: from 75 to 87 suspects
The maxi investigation, carried out by the Nas, then closed but brought further 'earthquake' shocks within the Parma health system: the suspects rose from 75 to 87 with various accusations, from criminal association to embezzlement, to abuse of office, from fraud to forgery. Executives and doctors are involved: for eleven people and two companies, the Public Prosecutor's Office has asked for the filing. Sixteen companies are accused of violating Law 231 for not having planned organized models that could prevent their employees from committing crimes. Among the suspects there is also the secretary of Guido Fanelli, the luminary of pain therapy who, according to the accusations, was the number one of the criminal association: the woman, in fact, would have obtained a scholarship, again according to the accusations, thanks to a tender "specially prepared so that she would be the winner". According to the prosecutor's office, his task would have been to manage relations with pharmaceutical companies 
and don't search. It was asked there'storage for Ennio Amori, Cristina Baroni, Svitlana Gorenko, Maria Assunta Martini, Barbara Bigi, Adele Antonella Giordano, Giorgia Maria Cacciani, Giorgio Mardegan, Ilaria Guidani, Antonella Croce, Massimo Natullo.
Eight other doctors under investigation: the 'court' of Fanelli
According to the reconstruction of the Public Prosecutor's Office, which filed the documents of the maxi investigation, Guido Fanelli allegedly managed the hospital department of the Second Anesthesia and Intensive Care Unit like a court, to which he brought people he liked. Precisely for this reason, two competitions also ended up in the investigators' sights, the call for two posts as medical director of the Second Anesthesia in November 2016: the candidates who should have passed the tests would also have been delivered the applications in advance. Between March and June 2017 Salici, Biondini, Valente and Di Pasquale were hired: the doctors of the Commission and the doctors hired were investigated for abuse of office. In September 2014 Fanelli would have piloted a competition to hire Marchesini: he and the doctors of the Commission are under investigation for abuse of office. The accusation against the head of Occupational Medicine Antonio Mutti, on the other hand, is of embezzlement: according to the indictment, he would have played a role in the affair of the master's shares. The accusation against Dario Bugada instead is abuse of office: he allegedly administered a combination of drugs to patients, however violating the discipline on clinical trials with the aim of favoring Teleflex.
